IONS

SEC source: 0000874015-21-000085 · edgardoc.xml · nonDerivative · entry 5

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on June 30, 2021. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.

SEC source: 0000874015-21-000085 · edgardoc.xml · nonDerivative · entry 4

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,683

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.

SEC source: 0000874015-21-000085 · edgardoc.xml · nonDerivative · entry 3

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on June 30, 2021. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.

SEC source: 0000874015-21-000085 · edgardoc.xml · nonDerivative · entry 2

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,683

F2 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.

SEC source: 0000874015-21-000085 · edgardoc.xml · nonDerivative · entry 1

MUTO FREDERICK T · CIK 0001181560 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on June 30, 2021. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.

SEC source: 0000874015-21-000082 · edgardoc.xml · derivative · entry 2

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,775

Underlying: Common Stock · 3,555 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-21-000082 · edgardoc.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

F1 · shares: Acquired pursuant to vesting and release of shares pursuant to a Restricted Stock Unit Award.

SEC source: 0000874015-21-000072 · edgardoc.xml · derivative · entry 3

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 5,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000072 · edgardoc.xml · nonDerivative · entry 2

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,199

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000072 · edgardoc.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,159

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000058 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,114

F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

F2 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 10/7/2019.

SEC source: 0000874015-21-000070 · edgar.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP, Research

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,295

F1 · kind: Reporting 460 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 460 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000068 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,699

F1 · kind: Reporting 197 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 197 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000066 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,587

F1 · kind: Reporting 116 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 116 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000064 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,920

F1 · kind: Reporting 414 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 414 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000062 · edgar.xml · nonDerivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 492

F1 · kind: Reporting 492 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 492 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000058 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,350

F1 · kind: Reporting 247 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 247 shares may not be sold until August 26, 2021

SEC source: 0000874015-21-000060 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,620

F1 · kind: Reporting 112 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 26, 2021. These 112 shares may not be sold until August 26, 2021.

SEC source: 0000874015-21-000053 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,103

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000053 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,409

F1 · shares: Represents shares earned upon the vesting of performance based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 69.7% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0000874015-21-000051 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,021

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.00 to $64.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

SEC source: 0000874015-21-000049 · edgar.xml · nonDerivative · entry 1

O'NEIL PATRICK R. · CIK 0001564926 · EVP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,502

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 6, 2020.

SEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By trust

Disclosed balance after: 494,391

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $62.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) of this Form 4.

SEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By trust

Disclosed balance after: 534,391

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.25 to $62.15, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.

SEC source: 0000874015-21-000047 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By trust

Disclosed balance after: 555,433

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on January 2, 2020.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $61.00, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) of this Form 4.

SEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 8

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 7,801

Underlying: Common Stock · 4,371 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 7

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,885

Underlying: Common Stock · 47,257 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000045 · edgar.xml · derivative · entry 6

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,333

Underlying: Common Stock · 5,333 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 4

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 3,111

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 3

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Indirect · By wife

Disclosed balance after: 4,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 2

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,354

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000045 · edgar.xml · nonDerivative · entry 1

CROOKE STANLEY T · CIK 0000897667 · Director · Exec Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000043 · edgar.xml · derivative · entry 1

Cadoret-Manier Onaiza · CIK 0001799355 · Chief Corp Dev and Cml Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,228

Underlying: Common Stock · 24,228 shares

Expires not disclosed

F1 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000041 · edgar.xml · derivative · entry 4

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,641

Underlying: Common Stock · 15,520 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000041 · edgar.xml · derivative · entry 3

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,822

Underlying: Common Stock · 20,822 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000041 · edgar.xml · nonDerivative · entry 2

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,508

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000041 · edgar.xml · nonDerivative · entry 1

BENNETT C FRANK · CIK 0001073387 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000039 · edgar.xml · derivative · entry 4

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,246

Underlying: Common Stock · 17,598 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000039 · edgar.xml · derivative · entry 3

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,714

Underlying: Common Stock · 22,714 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000039 · edgar.xml · nonDerivative · entry 2

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,506

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000039 · edgar.xml · nonDerivative · entry 1

Geary Richard S · CIK 0001442730 · EVP, Chief Development Offc

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000037 · edgar.xml · derivative · entry 4

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,199

Underlying: Common Stock · 17,151 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000037 · edgar.xml · derivative · entry 3

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,129

Underlying: Common Stock · 27,129 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000037 · edgar.xml · nonDerivative · entry 2

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,471

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000037 · edgar.xml · nonDerivative · entry 1

HOUGEN ELIZABETH L · CIK 0001074773 · EVP, Finance & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-21-000035 · edgar.xml · derivative · entry 5

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,243

Underlying: Common Stock · 34,823 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000035 · edgar.xml · derivative · entry 4

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,447

Underlying: Common Stock · 77,447 shares

Expires not disclosed

F6 · derivative.exercise_price: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F7 · derivative.exercise_price: Grant to reporting person of Performance Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F6 · derivative.exercise_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

F6 · derivative.expiration_date: Represents an award of performance based restricted stock units ("PRSUs"). One-third of the PRSUs may vest at the end of three separate performance periods spread over the three years following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 150% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of each performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-21-000035 · edgar.xml · derivative · entry 3

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,610

Underlying: Common Stock · 66,610 shares

Expires not disclosed

F3 · derivative.exercise_price: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal monthly installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.

SEC source: 0000874015-21-000035 · edgar.xml · nonDerivative · entry 2

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,775

F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

SEC source: 0000874015-21-000035 · edgar.xml · nonDerivative · entry 1

Monia Brett P · CIK 0001537529 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.